Localization and molecular interactions of mitoxantrone within living K562 cells as probed by confocal spectral imaging analysis

被引:52
作者
Feofanov, A
Sharonov, S
Kudelina, I
Fleury, F
Nabiev, I
机构
[1] UNIV REIMS,UFR PHARM,LAB SPECT BIOMOL,F-51096 REIMS,FRANCE
[2] RUSSIAN ACAD SCI,SHEMYAKIN & OVCHINNIKOV INST BIOORGAN CHEM,MOSCOW 117871,RUSSIA
基金
俄罗斯基础研究基金会;
关键词
D O I
10.1016/S0006-3495(97)78356-5
中图分类号
Q6 [生物物理学];
学科分类号
071011 [生物物理学];
摘要
Studying mechanisms of drug antitumor action is complicated by the lack of noninvasive methods enabling direct monitoring of the state and interactions of the drugs within intact viable cells. Here we present a confocal spectral imaging (CSI) technique as a method of overcoming this problem. We applied this method to the examination of localization and interactions of mitoxantrone (1, 4-dihydroxy-5, 8-bis-(([2-(2-hydroxyethyl)-amino]ethyl)amino-9,10-anthracenedione dihydrochloride), a potent antitumor drug, in living K562 cells. A two-dimensional set of fluorescence spectra of mitoxantrone (MITOX) recorded with micron resolution within a drug-treated cell was analyzed to reveal formation of drug-target complexes and to create the maps of their intracellular distribution. The analysis was based on detailed in vitro modeling of drug-target (DNA, RNA, DNA topoisomerase II) interactions and environmental effects affecting drug fluorescence. MITOX exposed to aqueous intracellular environment, MITOX bound to hydrophobic cellular structures, complexes of MITOX with nucleic acids, as well as the naphtoquinoxaline metabolite of MITOX were simultaneously detected and mapped in K562 cells. These states and complexes are known to be immediately related to the antitumor action of the drug. The results obtained present a basis for the subsequent quantitative analysis of concentration and time-dependent accumulation of free and bound MITOX within different compartments of living cancer cells.
引用
收藏
页码:3317 / 3327
页数:11
相关论文
共 29 条
[1]
ARLIN Z, 1990, LEUKEMIA, V4, P177
[2]
BURSTEIN EA, 1976, BIOPHYSICS, V6
[3]
DAGRA P, 1989, BIOCHIM BIOPHYS ACTA, V989, P163
[4]
MOLECULAR AND BIOCHEMICAL PHARMACOLOGY OF MITOXANTRONE [J].
DURR, FE ;
WALLACE, RE ;
CITARELLA, RV .
CANCER TREATMENT REVIEWS, 1983, 10 :3-&
[5]
PHARMACOKINETICS AND METABOLISM OF MITOXANTRONE - A REVIEW [J].
EHNINGER, G ;
SCHULER, U ;
PROKSCH, B ;
ZELLER, KP ;
BLANZ, J .
CLINICAL PHARMACOKINETICS, 1990, 18 (05) :365-380
[6]
MITOXANTRONE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN THE CHEMOTHERAPY OF CANCER [J].
FAULDS, D ;
BALFOUR, JA ;
CHRISP, P ;
LANGTRY, HD .
DRUGS, 1991, 41 (03) :400-449
[7]
A NEW CONFOCAL STIGMATIC SPECTROMETER FOR MICRO-RAMAN AND MICROFLUORESCENCE SPECTRAL IMAGING ANALYSIS - DESIGN AND APPLICATIONS [J].
FEOFANOV, A ;
SHARONOV, S ;
VALISA, P ;
DASILVA, E ;
NABIEV, I ;
MANFAIT, M .
REVIEW OF SCIENTIFIC INSTRUMENTS, 1995, 66 (05) :3146-3158
[8]
FUJIMOTO S, 1982, CANCER CHEMOTH PHARM, V8, P157
[9]
QUANTITATIVE STUDY OF DOXORUBICIN IN LIVING CELL-NUCLEI BY MICROSPECTROFLUOROMETRY [J].
GIGLI, M ;
DOGLIA, SM ;
MILLOT, JM ;
VALENTINI, L ;
MANFAIT, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 950 (01) :13-20
[10]
Grogan WM., 1990, Guide to flow cytometry methods